A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Manus Neurodynamica Secures £2.6m

Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has closed a £2.6m funding round to support the commercialisation of its innovative NeuroMotor PenTM – a medical device to aid diagnosis and monitoring of neuromotor disorders including Parkinson’s disease.

Existing investors supported the £2.6m investment round including the North East Innovation Fund, supported by the European Regional Development Fund, and managed by Northstar Ventures co-leading the round with Par Equity with participation from SIS Ventures, Scottish Enterprise and Old College Capital.

The funding will allow Manus to continue its launch into the EU pharmacy retail sector, focused on prevention screening, and global clinical markets, helping to differentiate between Parkinson’s and other movement disorders, aiding the patient pathway and reducing costs. Manus has already made solid progress here having signed an agreement earlier this month with Medispa, an Italian provider of wellness management systems and services, to integrate the NeuroMotor PenTM with Medispa’s Prevention Suite, an integrated platform of health services aimed at monitoring the health and well-being of patients. The funds will also support the Company’s application for US FDA regulatory clearance and progressing its US trials, as well as further developing and implementing its US commercialisation strategy.

The Company recently announced it has received funding from Johnson & Johnson Innovation to further the utility of the NeuroMotor PenTM into immunotherapy. Although funding has been received directly from J&J to undertake a clinical trial for the detection of neuromotor adverse effects following CAR T-cell therapy, the funding round will support optimising the configuration of the NeuroMotor PenTM for this indication. Furthermore, it will support development of the pen in other neurological conditions, such as Alzheimer’s disease.

Dr Rutger Zietsma, CEO of Manus, commented: “I’d like to thank Manus’ existing investors for supporting the Company’s commercialisation programme of our unique NeuroMotor PenTM, building on previous support we received in 2021. This year is set to be an exciting one, with partnerships already secured, and we truly believe our non-invasive and CE-marked product can have a huge impact on patients and tackle the unmet need for a quick, inexpensive device that can detect neurological conditions, particularly given the aging global population.”

Richard Charnley, Investment Director of Northstar Ventures, stated: “At Northstar Ventures we back businesses that are reimagining the future of healthcare, with a particular focus on healthy ageing. Having relocated its North East office from Durham to Gosforth in Newcastle to accommodate a growing team, we are excited by the potential impact Manus can have on those with neurological conditions and we were delighted to further support its mission.”

Alastair Moore, Senior Investment Manager at Par Equity added: “Manus is rapidly establishing itself as a go-to diagnostic for neurological conditions and with funding secured to now obtain US regulatory clearance off the back of achieving FDA breakthrough status, the next 18 months promise to be transformational. The NeuroMotor Pen’s ability to rapidly and non-invasively determine whether an individual requires further care has potential to deliver enormous efficiency gains for health systems while enabling the individual to have clarity on the meaning of their symptoms within minutes.”

Kerry Sharp, Director of Entrepreneurship and Investment at Scottish Enterprise said: “Encouraging innovative firms such as Manus to commercialise and scale is a priority for Scottish Enterprise. The NeuroMotor Pen developed by Manus aids clinicians in determining neurological conditions in a non-evasive manner and this investment will allow the company to progress this technology further, delivering potential growth opportunities and medical advances in the process.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy